Pharma-Bio Serv, Inc. reported a revenue of approximately $9.0 million for the fiscal year ending October 31, 2025, reflecting a decrease of $0.5 million compared to the previous year’s revenue of $9.5 million. The decline was primarily attributed to reduced project revenues in Puerto Rico, the United States, and Brazil, which offset a significant increase of $1.2 million in the European market. Despite the decrease in total revenue, the company experienced an improvement in gross profit margin, which increased by 5.8 percentage points, driven by enhanced margins in the Puerto Rico and U.S. consulting markets, along with a high-margin project in Europe.
The company’s cost of services decreased to $6.1 million from $6.99 million in the prior year, contributing to the improved gross profit of $2.91 million, up from $2.52 million. Selling, general, and administrative expenses also saw a reduction, totaling approximately $3.5 million, down from $3.8 million in the previous year. The net loss for the year was approximately $0.1 million, a significant improvement from a net loss of $0.78 million in the prior year, resulting in a loss per share of $0.004, compared to a loss of $0.034 per share in 2024.
Pharma-Bio Serv operates in three reportable segments: Puerto Rico, the United States, and Europe. The company serviced around 70 customers, including major pharmaceutical and biotechnology firms, during the fiscal year. The company has also transitioned to a virtual operational model, having moved its headquarters to a remote setup following the expiration of its office lease in December 2025. This strategic shift is expected to enhance operational efficiency and reduce overhead costs.
The company continues to pursue growth opportunities in the U.S., European, and Latin American markets, leveraging its established relationships with major clients. However, it faces challenges such as economic pressures in the pharmaceutical industry, potential changes in tax laws, and the competitive landscape of the consulting market. The company has requested a renegotiation of its tax grant from the Puerto Rico Industrial Development Company, which could impact its future tax obligations.
Looking ahead, Pharma-Bio Serv aims to maintain its market presence while expanding its service offerings. The management believes that its current working capital of approximately $11.6 million is sufficient to meet anticipated expenses and contractual commitments over the next twelve months. However, the company acknowledges that various external factors, including economic conditions and industry trends, could influence its future performance and profitability.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv provides compliance consulting services to the pharmaceutical, biotech, medical device, cosmetic, and food industries. Its core offerings include regulatory compliance, validation, technology transfer, and engineering services across Puerto Rico, the U.S., Europe, and Brazil. The company leverages experienced professionals to serve major clients, focusing on quality, regulatory adherence, and market expansion within a fragmented, competitive industry.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.